Filtered By:
Specialty: Neurology
Drug: Pradaxa

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 127 results found since Jan 2013.

Do the Antithrombotic Therapy at the Time of Intracerebral Hemorrhage Influence Clinical Outcome? Analysis between the Difference of Antiplatelet and Anticoagulant Agents and Clinical Course
Background: It is controversial whether taking antiplatelet agents (APs) or anticoagulant agents (ACs) could influence clinical outcome after intracerebral hemorrhage (ICH).Methods: We retrospectively investigated 557 ICH patients between September 2008 and August 2013. We reviewed patients' characteristics, hematoma volume, deterioration (hematoma expansion, surgical hematoma evacuation, or death), and clinical outcome in modified Rankin Scale.Results: A total of 397 were classified as neither AP nor AC (“Nothing”), 81 as single AP (44 as aspirin [ASA], 22 as clopidogrel or ticlopidine [CLP/TIC], 7 as cilostazol, 8 as...
Source: Journal of Stroke and Cerebrovascular Diseases - June 23, 2014 Category: Neurology Authors: Takeshi Okada, Taizen Nakase, Masahiro Sasaki, Tatsuya Ishikawa Tags: Original Articles Source Type: research

Management of acute stroke in patients taking novel oral anticoagulants
Each year, 1·0–2·0% of individuals with atrial fibrillation and 0·1–0·2% of those with venous thromboembolism who are receiving one of the novel oral anticoagulants (dabigatran, rivaroxaban, or apixaban) can be expected to experience an acute ischemic stroke. Additionally, 0·2–0·5% of individuals with atrial fibrillation who are receiving one of the novel oral anticoagulants can be expected to experience an intracranial hemorrhage. This opinion piece addresses the current literature and offers practical approaches to the management of patients receiving novel oral anticoagulants who present with an ischemic or ...
Source: International Journal of Stroke - June 1, 2014 Category: Neurology Authors: Graeme J. Hankey, Bo Norrving, Werner Hacke, Thorsten Steiner Tags: Review Source Type: research

Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry
Discussion: Our pilot data indicate that dabigatran appears to be safe for secondary stroke prevention during the first year of implementation of this therapy. However, high cost may limit the long-term treatment of AF patients with dabigatran, leading to early discontinuation.
Source: Therapeutic Advances in Neurological Disorders - April 22, 2014 Category: Neurology Authors: Tsivgoulis, G., Krogias, C., Sands, K. A., Sharma, V. K., Katsanos, A. H., Vadikolias, K., Papageorgiou, S. G., Heliopoulos, I., Shiue, H., Mitsoglou, A., Liantinioti, C., Athanasiadis, D., Giannopoulos, S., Piperidou, C., Voumvourakis, K., Alexandrov, A. Tags: Original Research Source Type: research

Dabigatran -The Future Of Cortical Venous Thrombosis Therapy -A Case Series Study (P6.025)
ConclusionsAs these cases demonstrate, Dabigatran appears be effective and safe in the treatment of single cortical venous sinus thrombosis . However large scale randomized controlled trials will be required to confirm its efficacy as a therapeutic modality .Disclosure: Dr. Mathew has nothing to disclose. Dr. Alexander has nothing to disclose. Dr. Sarma has nothing to disclose. Dr. Nadig has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Mathew, T., Alexander, L., Sarma, G., Nadig, R. Tags: General Neurology VI Source Type: research

Presentation, therapy and outcome of patients with ischemic stroke under new oral anticoagulants.
CONCLUSIONS: Little is known about ischemic strokes under NOAC. To increase the knowledge, the data of 469 ischemic strokes which occurred in NOAC-investigating trials should be analyzed. Furthermore ischemic and bleeding events under NOAC outside clinical trials should be reported. An international registry, independent from the pharmaceutical industry for collecting these informations is desirable. PMID: 24821640 [PubMed - as supplied by publisher]
Source: Neurologia i Neurochirurgia Polska - March 1, 2014 Category: Neurology Authors: Stöllberger C, Finsterer J Tags: Neurol Neurochir Pol Source Type: research

Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology
Objective: To update the 1998 American Academy of Neurology practice parameter on stroke prevention in nonvalvular atrial fibrillation (NVAF). How often do various technologies identify previously undetected NVAF? Which therapies reduce ischemic stroke risk with the least risk of hemorrhage, including intracranial hemorrhage? The complete guideline on which this summary is based is available as an online data supplement to this article. Methods: Systematic literature review; modified Delphi process recommendation formulation. Major conclusions: In patients with recent cryptogenic stroke, cardiac rhythm monitoring probabl...
Source: Neurology - February 24, 2014 Category: Neurology Authors: Culebras, A., Messe, S. R., Chaturvedi, S., Kase, C. S., Gronseth, G. Tags: All Cerebrovascular disease/Stroke SPECIAL ARTICLE Source Type: research

Response to Letter Regarding Article, "Dabigatran Versus Warfarin: Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation" Letters to the Editor
Source: Stroke - February 24, 2014 Category: Neurology Authors: Hori, M., Ezekowitz, M. D., Reilly, P. A. Tags: Health policy and outcome research, Coumarins, Other anticoagulants, Acute Cerebral Hemorrhage, Acute Cerebral Infarction Letters to the Editor Source Type: research

Recurrent Ischemic Stroke in a Patient with the Trousseau Syndrome Treated with Dabigatran
A 70-year-old man with multiple ischemic strokes was diagnosed with cardiac embolism and treated with dabigatran. Three months later, he suddenly developed vertigo and vomiting. Magnetic resonance imaging, showed recurrent lesions and blood tests revealed hypercoagulability, hypoproteinemia, and elevated cytokeratin 19 fragments that serve as a tumor marker of lung cancer. Chest computed tomography showed there were small nodules in bilateral lungs and swollen mediastinal lymph nodes. A conclusive diagnosis was impossible because the patient declined invasive procedures. We suspected primary lung cancer and diagnosed conco...
Source: Journal of Stroke and Cerebrovascular Diseases - February 21, 2014 Category: Neurology Authors: Kosuke Yoshida, Takashi Kimura, Yoko Aburakawa, Yasuhiro Suzuki, Kenji Kuroda, Osamu Yahara Tags: Case Reports Source Type: research

Proposed Approach to Thrombolysis in Dabigatran-Treated Patients Presenting with Ischemic Stroke
Source: Journal of Stroke and Cerebrovascular Diseases - January 9, 2014 Category: Neurology Authors: Mahesh Kate, Artur Szkotak, Adam Witt, Ashfaq Shuaib, Kenneth Butcher Tags: Original Articles Source Type: research

Cardio Notes: Societies Issue Top 10 List
(MedPage Today) -- The American Heart Association and the American Stroke Association have compiled the top 10 advances in heart disease and stroke research of 2013, and the safety of dabigatran (Pradaxa) will be examined again.
Source: MedPage Today Neurology - January 6, 2014 Category: Neurology Source Type: news

Dabigatran-related Intracerebral Hemorrhage Resulting in Hematoma Expansion
We present a case that suggests that hematoma expansion may occur after NOAC-related ICH.
Source: Journal of Stroke and Cerebrovascular Diseases - October 7, 2013 Category: Neurology Authors: Claus Z. Simonsen, Thorsten Steiner, Anna Tietze, Dorte Damgaard Tags: Case Reports Source Type: research

Letter by Kawada Regarding Article, "Dabigatran Versus Warfarin: Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation" Letters to the Editor
Source: Stroke - September 23, 2013 Category: Neurology Authors: Kawada, T. Tags: Anticoagulants Letters to the Editor Source Type: research

Imaging of Contrast Medium Extravasation in Anticoagulation-Associated Intracerebral Hemorrhage With Dual-Energy Computed Tomography Basic Sciences
Conclusions— Dual-energy computed tomography allows quantifying CE, as a marker of ongoing bleeding, in a model of anticoagulation-associated ICH. Dabigatran induces less CE in ICH than warfarin and consequently reduces risks of hematoma expansion. This constitutes a potential safety advantage of dabigatran over warfarin. Nevertheless, in case of warfarin anticoagulation, prothrombin complex concentrates reduce this side effect.
Source: Stroke - September 23, 2013 Category: Neurology Authors: Won, S.-Y., Schlunk, F., Dinkel, J., Karatas, H., Leung, W., Hayakawa, K., Lauer, A., Steinmetz, H., Lo, E. H., Foerch, C., Gupta, R. Tags: Coumarins, Other anticoagulants, Other Treatment, Acute Cerebral Hemorrhage, Intracerebral Hemorrhage Basic Sciences Source Type: research